Efficacy and safety of alirocumab in reducing lipids and cardiovascular events". The New England Journal of Medicine - 2015

Brief Summary:

In patients at high risk for cardiovascular events by virtue of a confirmed diagnosis of heterozygous familial hypercholesterolemia, established coronary disease, or a coronary disease equivalent followed for 1.5 years, the use of the monoclonal antibody alirocumab in addition to high-intensity statin therapy resulted in an additional 62% reduction in LDL cholesterol with no significant increase in serious adverse events. Furthermore, a post-hoc analysis demonstrated a 2% absolute risk reduction in major adverse cardiovascular events with alirocumab therapy.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/25773378